Defining SaeR/S-dependent Neutrophil-S. aureus Interactions that Determine the Outcome of Infection

Information

  • Research Project
  • 10194360
  • ApplicationId
    10194360
  • Core Project Number
    R01AI149491
  • Full Project Number
    5R01AI149491-02
  • Serial Number
    149491
  • FOA Number
    PA-19-056
  • Sub Project Id
  • Project Start Date
    6/16/2020 - 4 years ago
  • Project End Date
    5/31/2025 - 4 months from now
  • Program Officer Name
    HUNTLEY, CLAYTON C
  • Budget Start Date
    6/1/2021 - 3 years ago
  • Budget End Date
    5/31/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    02
  • Suffix
  • Award Notice Date
    5/21/2021 - 3 years ago

Defining SaeR/S-dependent Neutrophil-S. aureus Interactions that Determine the Outcome of Infection

Staphylococcus aureus (S. aureus) is one of the most frequent causes of bacterial infections in the U.S. and is responsible for diverse types of infections ranging in severity from mild to fatal in both hospital and community settings. In the community, S. aureus typically causes skin-and-soft-tissue infections with an estimated 12 ? 13 million outpatient visits per-year (in the U.S.) but can also cause severe manifestations including necrotizing fasciitis and sepsis in individuals with no underlying risk. One of the most clinically significant aspects of S. aureus infections is the high prevalence of drug resistance and the innate ability for S. aureus to develop resistance to antibiotics making it very difficult to develop therapeutics that will have potential for long-term efficacy on S. aureus. The research proposed in this application will broaden our understanding of host- pathogen interactions, providing the foundation for future studies aimed at the intelligent design of novel vaccines and therapies to treat bacterial infection. To that end, this project will study how S. aureus uses the SaeR/S two-component gene regulatory system to evade innate immunity. The SaeR/S system is essential for evasion of neutrophil killing; however, exact mechanisms dependent on SaeR/S resulting in neutrophil dysfunction are not defined. Three specific Aims will test the hypothesis that the SaeR/S-mediated up- regulation of S. aureus virulence genes undermines an effective neutrophil response that would normally clear infection. In Aim One, host pathogen RNA expression via RNA-seq will be used to determine the direct influence of SaeR/S-regulated bacterial genes on human neutrophil gene expression as well as resolve the individual contribution of SaeR/S components on neutrophil and pathogen gene expression simultaneously. In Aim Two, we will determine how SaeR/S-dependent changes in neutrophil human myeloperoxidase (MPO) activity and the production reactive oxygen species (ROS) alters neutrophil apoptosis and neutrophil extracellular trap (NET) formation. In Aim Three, we will utilize a novel ex vivo model of neutrophil priming by stimulated PBMCs to determine the role of initial SaeR/S-mediated immune cell interactions on subsequent neutrophil function. These ex vivo primary human cell studies will be complemented with murine models of infection to thoroughly evaluate these immune responses. Findings from experiments outlined in this proposal will improve our overall understanding of host-pathogen interactions by specifically characterizing novel SaeR/S-mediated mechanisms used by S. aureus to overcome an effective neutrophil response. Collectively this research will address our long-term objective to characterize reciprocal response pathways between host and pathogen that will highlight key factors needed for both the pathogen to cause infection and for the host to resolve disease. Results will provide valuable information for vaccine and immunotherapeutic development.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R01
  • Administering IC
    AI
  • Application Type
    5
  • Direct Cost Amount
    470720
  • Indirect Cost Amount
    138266
  • Total Cost
    608986
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
    EARTH SCIENCES/RESOURCES
  • Funding ICs
    NIAID:608986\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    HIBP
  • Study Section Name
    Host Interactions with Bacterial Pathogens Study Section
  • Organization Name
    MONTANA STATE UNIVERSITY - BOZEMAN
  • Organization Department
    MICROBIOLOGY/IMMUN/VIROLOGY
  • Organization DUNS
    625447982
  • Organization City
    BOZEMAN
  • Organization State
    MT
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    597170000
  • Organization District
    UNITED STATES